EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target

Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, Shu-Ya Cao, Chen-Yu Jiao, Ming Lu, Biao Zhang, Yue Yang, Qing Xu, Xiao-Feng Wu, Ke Wang, Yong-Xiang Xia und 2 weitere

Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 935-959

DOI: 10.3350/cmh.2024.0895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Gu-Wei Ji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Immunotherapy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Identifying patients with intrahepatic cholangiocarcinoma (ICC) likely to benefit from immunochemotherapy, the new front-line treatment, remains challenging. We aimed to unveil a novel radiotranscriptomic signature that can facilitate treatment response prediction by multi-omics integration and multiscale modelling.

Methods

We analyzed bulk, single-cell and spatial transcriptomic data comprising 457 ICC patients to identify an immune-related score (IRS), followed by decoding its spatial immune context. We mapped radiomics profiles onto spatial-specific IRS using machine learning to define a novel radiotranscriptomic signature, followed by multi-scale and multi-cohort validation covering 331 ICC patients. The signature was further explored for the potential therapeutic target from in vitro to in vivo.

Results

We revealed a novel 3-gene (PLAUR, CD40LG, and FGFR4) IRS whose down-regulation correlated with better survival and improved sensitivity to immunochemotherapy. We highlighted functional IRS-immune interactions within tumor epithelium, rather than stromal compartment, irrespective of geospatial locations. Machine learning pipeline identified the optimal 3-feature radiotranscriptomic signature that was well-validated by immunohistochemical assays in molecular cohort, exhibited favorable external prognostic validity with C-index over 0.64 in resection cohort, and predicted treatment response with an area under the curve of up to 0.84 in immunochemotherapy cohort. We also showed that anti-uPAR/PLAUR alone or in combination with anti-programmed cell death protein 1 therapy remarkably curbed tumor growth, using in vitro ICC cell lines and in vivo humanized ICC patient-derived xenograft mouse models.

Conclusions

This proof-of-concept study sheds light on the spatially-resolved radiotranscriptomic signature to improve patient selection for emerging immunochemotherapy and high-order immunotherapy combinations in ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsImmunotherapyHumansFemalePrognosisCell Line, TumorMaleAnimalsMiceTranscriptomeMachine LearningMiddle Aged

Stichwörter der Autor:innen

Intrahepatic cholangiocarcinomaMachine learningMulti-omics profilingPrediction modelRadiogenomics

Autor:innen und Institutionen

  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, China.
  • NHC Key laboratory of Hepatobiliary Cancers, Nanjing, China.
  • Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of General Surgery, Yancheng No.1 People's Hospital, Yancheng, China.
  • Department of General Surgery, The First People's Hospital of Changzhou, Changzhou, China.

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Ji, G. W., Xu, Z. G., Liu, S. C., Cao, S. Y., Jiao, C. Y., Lu, M., Zhang, B., Yang, Y., Xu, Q., Wu, X. F., Wang, K., Xia, Y. X., Li, X. C., & Wang, X. H. (2025). Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target. Clinical and Molecular Hepatology, 31(3), 935-959. https://doi.org/10.3350/cmh.2024.0895

Vancouver

Ji GW, Xu ZG, Liu SC, Cao SY, Jiao CY, Lu M, et al. Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target. Clinical and Molecular Hepatology. 2025;31(3):935-959. doi:10.3350/cmh.2024.0895

BibTeX
@article{Ji2025,
  author = {Ji, Gu-Wei and Xu, Zheng-Gang and Liu, Shuo-Chen and Cao, Shu-Ya and Jiao, Chen-Yu and Lu, Ming and Zhang, Biao and Yang, Yue and Xu, Qing and Wu, Xiao-Feng and Wang, Ke and Xia, Yong-Xiang and Li, Xiang-Cheng and Wang, Xue-Hao},
  title = {Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {935--959},
  doi = {10.3350/cmh.2024.0895}
}
Kostenlos starten →